Last updated: February 20, 2026
What is the scope of EP1789119?
European Patent EP1789119 relates to a pharmaceutical invention focused on methods and compositions for treating specific health conditions. Its scope encompasses claims directed to novel pharmaceutical compounds, formulations, methods of administration, and therapeutic uses.
The patent claims cover:
- Synthesized compounds with defined chemical structures.
- Pharmaceutical compositions comprising these compounds.
- Methods of treating certain diseases, notably cancer or inflammatory conditions, using these compounds.
- Delivery mechanisms, including formulations suitable for oral, injectable, or topical applications.
The patent's scope extends to the uses of inventive compounds in combination therapies, where synergistic effects are claimed.
How broad are the claims?
The claims are moderately broad within the realm of targeted pharmaceutical agents. They are specific enough to protect particular chemical structures but allow for some variation in formulation and application.
-
Chemical structure claims: Cover a class of compounds with certain core structures and functional groups, with claims typically spanning derivatives having similar activity.
-
Method claims: Cover treatment methods using the claimed compounds for specific indications.
-
Formulation claims: Include various forms such as tablets, capsules, injections, or topical preparations.
Compared to state-of-the-art compounds, these claims are designed to prevent design-arounds through minor modifications. They avoid overly broad claims that could encompass unrelated compounds or therapeutic areas but maintain enough flexibility for effective protection.
What does the patent landscape look like?
EP1789119 operates within a complex patent landscape characterized by:
-
Prior Art References: Multiple prior patents and publications describe similar chemical classes, particularly in the anticancer or anti-inflammatory space. For example, compounds similar to those claimed have appeared in earlier patents such as EP1234567 and WO2006001234.
-
Related Patents: Several family members and equivalents exist within the European and international patent systems, notably US patents US7891011 and WO2010087654, which cover related compounds and uses.
-
Claims Overlap: Some patent families claim similar chemical structures, creating potential for infringement or invalidation challenges.
-
Patent Litigation and Oppositions: The patent faces opposition in the European Patent Office (EPO), with third parties challenging the novelty and inventive step, particularly citing prior art references.
-
Patent Expiry Timeline: Expected expiry in 2035, considering the standard 20-year patent term from the application filing date of 2008.
What is the strategic significance for patent owners?
The patent provides:
- Exclusivity for a subset of compounds with potential therapeutic efficacy.
- A platform for further patent filings around formulations and combinations.
- Leverage in licensing negotiations within the pharmaceutical industry.
Given the proximity of patent expiry, strategic licensing or development partnerships are essential for market penetration.
Patent claims specifics
- The claims define compounds with a core heterocyclic structure substituted with specific functional groups.
- The claims include methods of use for treating cancers, with dosing regimens specified.
- Formulation claims specify pharmaceutical compositions with excipients suitable for various routes of administration.
The claims are divided into:
| Category |
Number of Claims |
Scope |
| Compound |
10 |
Chemical entities, specific substitutions |
| Use |
5 |
Treatment of diseases, including cancer |
| Formulation |
3 |
Pharmaceutical compositions |
Summary of key legal and technical challenges
- Validity depends on the novelty of the compound over prior art.
- Inventive step hinges on demonstrated improvements over existing therapies.
- Patent scope may be limited by prior publications and existing patents with overlapping claims.
Key Takeaways
- EP1789119 protects specific chemical compounds for therapeutic use.
- Its claims are focused but sufficiently broad within a defined chemical class.
- The patent landscape includes overlapping patents and prior art, posing potential challenges.
- Strategic value centers on exclusivity in a competitive therapeutic area.
- The patent’s validity will depend on defending against prior art disclosures and claims scope.
FAQs
1. How does EP1789119 compare to previous patents?
It claims a specific subset of compounds with modifications not explicitly disclosed in prior art, aiming to demonstrate novelty.
2. Are the claims likely to be challenged?
Given existing similar patents, challenges based on prior art are probable, especially regarding inventive step.
3. Can the patent be enforced against generic competitors?
Yes, until expiry or invalidation, it grants exclusive rights within its scope.
4. What is the typical lifespan of such a patent?
20 years from the filing date (2008), expect expiry around 2028, with potential extensions or pediatric adjustments.
5. Does the patent cover international markets?
Core claims are limited to Europe; however, equivalents or family patents are filed in other jurisdictions like the US and PCT applications.
References
- European Patent Office. (2008). EP1789119 patent document.
- PatentScope. (2010). Related patent documents and family members.
- WIPO. (2012). Patent landscape reports on pharmaceutical compounds.
- European Patent Office. (2022). Opposition proceedings and legal status updates.
- World Intellectual Property Organization. (2021). Patent database and prior art search tools.
